Nefrocarnit (Levocarnitine)

Levocarnitine, the active ingredient in Nefrocarnit, is a carnitine supplement presented as an intravenous solution for parenteral use. It is indicated for primary carnitine deficiency, secondary carnitine deficiency, and metabolic disorders that require carnitine supplementation to support fatty‑acid oxidation in patients of all ages.

GNH USA supplies Nefrocarnit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for import. Customers benefit from reliable logistics and technical support.

Nefrocarnit is used to address carnitine deficiency states and related metabolic disorders. - Primary carnitine deficiency: restores intracellular carnitine levels to improve fatty‑acid oxidation and energy production. - Secondary carnitine deficiency: supplements depleted carnitine pools caused by renal loss, certain medications, or metabolic stress. - Metabolic disorders requiring carnitine supplementation: supports patients with organic acidemias or fatty‑acid oxidation disorders by facilitating mitochondrial transport of long‑chain fatty acids.

Intravenous levocarnitine may be associated with a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Injection site reactions: redness, swelling, or pain at the infusion site. - Headache: transient cranial discomfort. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Cardiac arrhythmias: irregular heart rhythm potentially linked to electrolyte shifts. - Metabolic acidosis: significant pH reduction in blood.

Before initiating therapy, consider the following precautions. - Renal impairment: adjust dose and monitor plasma carnitine levels. - Hepatic impairment: use with caution; monitor liver function tests. - Pediatric use: safety not fully established; consider risk‑benefit. - Concomitant valproic acid therapy: increased risk of hyperammonemia; monitor ammonia. - Monitor for hypersensitivity: observe for rash, bronchospasm, or anaphylaxis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levocarnitine may interact with other medicines; review the following. Major Interactions (Avoid): - Valproic acid: may increase risk of hyperammonemia and reduce efficacy. - Dialysis: extracorporeal removal can markedly decrease plasma levocarnitine levels. - Anticonvulsants (e.g., phenobarbital): may accelerate carnitine metabolism, lowering therapeutic effect. Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): levocarnitine may potentiate anticoagulant effect; monitor INR. - Thyroid hormone replacement: possible alteration of metabolic rate; assess thyroid function. - Diuretics (loop): may affect electrolyte balance; watch for hypotension.